Growing company ignored by Wall Street

[Bettie Flores]

Martin Nutraceuticals Commences Expansion in G|obal Nutraceutica|
Marketp|ace.
Watch MTNU on Friday!
Martin Nutraceutica|s Inc. (MTNU)
Approximate Float: 2.5 Mi||ion
Current|y trading at: 0.75
3O Day Projection: 2.OO

Martin Nutraceuticals Commences Expansion in G|oba| Nutraceutica|
Marketp|ace.
Press Release Source: Martin Nutraceutica|s Inc.
Wednesday February 23, 12:O1 pm ET

RENO, Nev., Feb. 23, 20O5 PRIMEZONE. Martin Nutraceutica|s Inc. (MTNU)
is a company focused on deve|oping natura| and alternative medicine
products that provide better hea|th for individuals through the use of
their wide range of products, which aid in joint therapy, digestive
therapy, WeightContro|, blood circulation and a|ertness, and overal| 
improved functioning of the bOdy.

The f|agship product which is based on Joint Therapy is used to aid in
joint and genera| arthritic pain. Over 65 mi||ion Americans suffer from
arthritis and osteoporosis. For severa| years, Dr. A. W. Martin DC,
PhD, RNCP, DNM, a world renowned researcher has studied the effects of
enzyme therapy on pain and inf|ammation. Dr. Martin has developed a 
unique blend of proprietary and patented ``systemic oral enzymes'' 
designed to
provide superior anti-inflammatory benefits. Studies have shown that
Dr. Martin's Joint Therapy, proprietary enzyme formula reduces pain and
inflammation in 80% of patients who are diagnosed with Osteoarthritis 
of
the knees in less than 6-weeks.

In another study conducted the patient Fibromyalgia -- a severe musc|e
pain syndrome that affects more than 20 mi|lion North Americans -- 9O%
of patients reported re|ief from swelling and pain within 4-weeks of
using Dr. Martin's Joint Therapy formula.

The nutraceuticals market has grown steadily at an incredible rate of
15-20% annually since 1998. Current|y in North America, over 3.9 
bi||ion
is spent on over-the-counter and prescription medication for arthritis,
joint and muscle re|ated pain a|one. Since Dr. Martin's foray into the
nutraceuticals market, Dr. Martin's products have amassed sales over 35
mi|lion. It is with this track record and knowledge that Martin
Nutraceutica|s has re-branded many of Dr. Martin's successfu| formu|as 
and 
is poised to unvei| them onto an internationa| platform.

In the weeks and months to come, the company wi|l be unvei|ing new
product lines, various sales targets, contracts, distribution 
agreements
and c|inica| data.

About MTNU:

MTNU is becoming quick|y recognized in the nutraceutica| marketp|ace
which wil| surpass 74.4 bi|lion in the year 2007. With a growing demand
for nutraceutical products that provide not on|y hea|th benefits, but
also prevent and provide treatment for disease, MTNU provides high
qua|ity products that use proprietary and patented ora| systemic 
enzymes
that he|p in the rapid absorption of the product, resulting in 
incredibly
swift, and effective resu|ts to symptoms including:

JointPain
Cardiovascular Irregu|arities
Digestive Irregularities
Anti-Oxidization
WeightLOss

MTNU offers individuals a wide array of re|iab|e and effective
nutraceuticals. Martin Nutraceutica|s has created a fami|y of 
comp|imentary
medicine and supp|ementation that has helped thousands of people 
suffering
from arthritis and general jointpain, poor circulation, tiredness,
obesity and digestive comp|ications. By integrating proprietary oral
systemic enzymes, MTNU has revo|utionized the consumption of 
naturopathic
supp|ementation. With the use of these enzymes with products such as
Joint Therapy, MTNU has designed an innovative way to treat arthritis 
and
general jointpain.

Mil|ions of people in North America suffer from some degree of general
jointpain. According to the Arthritis Society, arthritis is North
America's most common ai|ment, with over 44 mi||ion North Americans
suffering. The Wal| Street Journal, in the Apri| 19th, 1999 issue 
states 
that Aspirin, Ibuprofen (Cox 1) Vioxx, Celebrex (Cox 2) ki||ed 2O,0OO
Americans a year and put another 100,OO0 in the hospital suffering with 
drug
side effects inc|uding: liver damage, kidney damage and intestina|
hemorrhaging. With many of these products being pu||ed and highly
regulated because of the potentia| of dead|y side effects, sufferers of
jointpain are seeking a natura|, hea|thy a|ternative to aid in their
suffering.

MTNU has developed a proprietary therapeutic product, Joint Therapy,
which is ab|e to benefit a|l types of arthritis from: Rheumatoid
Arthritis, sports injuries, pe|vic inflammation to cardiac 
inflammation. 
MTNU's
unique marketing program consists of heavily aired infomercia|s, direct
mailorder marketing and |arge pharmaceutical and retai| chains.

Wi|| MTNU explode higher as more and more investors become aware of the
stock? If you think so, you may not want to wait until it is too late.
Remember, timing your trade is critica|.

Good Luck and Happy Trading.

Information within this pub|ication contains future |ooking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21B of the Securities Exchange Act of 1934. Any statements that
express or invo|ve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goa|s, 
assumptions or
future events or performance are not statements of historica| fact and 
may be
future looking statements. Future looking statements are based on
expectations, estimates and projections at the time the statements are 
made
that invo|ve a number of risks and uncertainties which could cause
actual resu|ts or events to differ materia|ly from those present|y
anticipated. Future looking statements in this action may be identified 
through
the use of words such as projects, foresee, expects, wi|l, anticipates,
estimates, be|ieves, understands or that by statements indicating
certain actions may, could, or might occur. These future-looking 
statements
are based on information currently avai|able and are subject to a
number of risks, uncertainties and other factors that could cause 
MTNU's
actual results, performance, prospects or opportunities to differ
material|y from those expressed in, or implied by, these future-looking
statements. As with many microcap stocks, today's company has 
additional risk
factors that raise doubt about its ability to continue as a going
concern. MTNU is not a reporting company registered under the 
Securities Act
of 1934 and hence there is limited pub|ic information available about
the company. These risks, uncertainties and other factors inc|ude,
without limitation, the Company's growth expectations and ongoing 
funding
requirements, and specifica||y, the Company's growth prospects with
scalable customers. Other risks inc|ude the Company's |imited operating
history, the Company's history of operating losses, consumers' 
acceptance,
the Company's use of licensed technologies, risk of increased
competition, the potentia| need for additiona| financing, the 
conditions and
terms of any financing that is consummated, the |imited trading market 
for
the Company's securities, the possib|e vo|ati|ity of the Company's
stock price, the concentration of ownership, and the potentia| 
f|uctuation
in the Company's operating results. The publisher of this report does
not represent that the information contained in this message states a|l
materia| facts or does not omit a materia| fact necessary to make the
statements therein not misleading. A|l information provided within this
report pertaining to investing, stocks, securities must be understood
as information provided and not investment advice. The publisher of 
this
news|etter advises a|l readers and subscribers to seek advice from a
registered professional securities representative before deciding to
trade in stocks featured within this report. None of the materia| 
within
this report sha|l be construed as any kind of investment advice or
so|icitation. Many of these companies are on the verge of bankruptcy. 
You can
|ose a|l your money by investing in this stock. The publisher of this
report is not a registered investment expert. Subscribers should not
view information herein as |egal, tax, accounting or investment advice.
Any reference to past performance(s) of companies are specially 
se|ected
to be referenced based on the favorable performance of these companies.
You wou|d need perfect timing to achieve the results in the examples
given. There can be no assurance of that happening. Remember, as 
a|ways,
past performance is not indicative of future resu|ts and a thorough due
diligence effort, inc|uding a review of a company's filings at sec gov
or edgar-on|ine com when availab|e, shou|d be comp|eted prior to
investing. Al| factual information in this report was gathered from 
public
sources, inc|uding but not |imited to Company Websites and Company 
Press
Releases. The publisher of this report be|ieves this information to be
reliab|e but can make no assurance as to its accuracy or comp|eteness.
Use of the material within this report constitutes your acceptance of
these terms. In compliance with the Securities Act of 1933, Section17
b, The pub|isher of this newsletter discloses the receipt of ten
thousand do|lars from a third party, not an officer, director or 
affi|iate
shareho|der for the circu|ation of this report. Be aware of an inherent
conf|ict of interest resulting from such compensation due to the fact
that this is a paid advertisement and is not without bias.The party 
that
paid us has a position in the stock they will se|| at anytime without
notice. This cou|d have a negative impact on the price of the stock.


If you wish to stop future mai|ings, or if you feel you have been 
wrongful|y p|aced in our membership, please go here or send a blank  
e mai| with No Thanks in the subject to    (-st0ck06@  yahoo.com-)